Fig. 1From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)Flow chart. Forty-five patients were eligible for study inclusionBack to article page